

March 7, 2019



VolitionRx Limited Schedules Full Year 2018 Earnings Conference Call and Business Update

Conference call to take place Thursday, March 14, 2019 at 8:30 am Eastern time

ISNES, Belgium, March 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call on Thursday, March 14 at 8:30 a.m. Eastern time to discuss its financial and operating results for the fourth quarter and full year 2018, in conjunction with the filing of its annual report on Form 10-K for the fourth quarter and full year ended December 31, 2018.

Event:	VolitionRx Limited Fourth Quarter & Full Year 2018 Earnings and Business Update Conference Call
Date:	Thursday, March 14, 2019
Time:	8:30 a.m. Eastern time
U.S. & Canada Dial-in:	1-877-407-9716 (toll free)
U.K. Dial-in:	0 800 756 3429 (toll free)
Toll/International:	1-201-493-6779
Conference ID:	13688493

Cameron Reynolds, President and Chief Executive Officer of Volition, will host the call along with David Vanston, Chief Financial Officer and Scott Powell, Executive Vice President, Investor Relations. The call will provide an update on recent developments and Volition's activities, including details of new and ongoing clinical trials, important events which have taken place in 2018, and milestones for 2019 and beyond.

A live audio webcast of the conference call will also be available on the investor relations page of Volition's corporate website at <http://ir.volitionrx.com>. In addition, a telephone replay of the call will be available until March 28, 2019. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13688493.

About Volition

Volition is a multi-national life sciences company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their

quality of life. The tests are based on the science of Nucleosomics[®], which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.

Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market.

Nucleosomics[®] is a trademark of Volition and its subsidiaries.

For more information about Volition, visit Volition's website (<http://www.volitionrx.com>) or connect with us via:

Twitter: <https://twitter.com/volitionrx>

LinkedIn: <https://www.linkedin.com/company/volitionrx>


Facebook: <https://www.facebook.com/VolitionRx/>

YouTube: <https://www.youtube.com/user/VolitionRx>

The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

Louise Batchelor, Volition mediarelations@volitionrx.com +44 (0)7557 774620	Scott Powell, Volition investorrelations@volitionrx.com +1 (646) 650 1351
Joseph Green, Edison Advisors jgreen@edisongroup.com +1 (646) 653 7030	

 View original content: <http://www.prnewswire.com/news-releases/volitionrx-limited-schedules-full-year-2018-earnings-conference-call-and-business-update-300808433.html>

SOURCE VolitionRx Ltd